Astellas to Launch Xospata (gilteritinib) for R/R Acute Myeloid Leukemia (AML) with FLT3 Mutation, in the US

 Astellas to Launch Xospata (gilteritinib) for R/R Acute Myeloid Leukemia (AML) with FLT3 Mutation, in the US

Astellas to Launch Xospata (gilteritinib) for R/R Acute Myeloid Leukemia (AML) with FLT3 Mutation, in the US

Shots:

  • On 28 Nov, 2018 Xospata (gilteritinib) received FDA approval as a PO monothx, indicated for r/r FLT3 mutation-positive (FLT3mut+) AML
  • Xospata is accompanied by Xospata Support Solutions offering access and reimbursement support to patients and also provides information regarding patient healthcare coverage options and financial assistance programs
  • Xospata 40 mg (gilteritinib) is a FLT3 inhibitor, approved by Japan Ministry of Health, Labor and Welfare (MHLW) for r/r AML with FLT3 mutations and is being evaluated in P-III for multiple FLT3 mutation-positive AML

Click here to read full press release/ article | Ref: Astellas | Image: Pharma Field

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post